Symbols / SAVA
SAVA Chart
About
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 118.35M |
| Enterprise Value | 12.27M | Income | -106.03M | Sales | — |
| Book/sh | 1.69 | Cash/sh | 2.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | 30 | IPO | — |
| P/E | — | Forward P/E | -1.38 | PEG | — |
| P/S | — | P/B | 1.45 | P/C | — |
| EV/EBITDA | -0.18 | EV/Sales | — | Quick Ratio | 2.23 |
| Current Ratio | 2.27 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.22 | EPS next Y | -1.77 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-09 | ROA | -24.80% |
| ROE | -85.44% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 48.31M |
| Shs Float | 42.98M | Short Float | 14.83% | Short Ratio | 8.50 |
| Short Interest | — | 52W High | 4.98 | 52W Low | 1.15 |
| Beta | -0.83 | Avg Volume | 892.61K | Volume | 2.24M |
| Target Price | $8.00 | Recom | None | Prev Close | $2.16 |
| Price | $2.45 | Change | 13.43% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.45
Latest analyst target
3. DCF / Fair value
$6.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.45
Low
$8.00
High
$8.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-06 | init | LUCID CAPITAL MARKETS | — → Buy | $8 |
| 2025-03-25 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-03-04 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-26 | down | HC Wainwright & Co. | Buy → Neutral | $116 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $116 |
| 2024-10-08 | up | HC Wainwright & Co. | Neutral → Buy | $116 |
| 2024-08-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-08 | reit | Rodman & Renshaw | Buy → Buy | $107 |
| 2024-07-19 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-07-01 | down | Jones Trading | Buy → Hold | — |
| 2024-07-01 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-05-17 | main | HC Wainwright & Co. | Buy → Buy | $131 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-07-06 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-05-11 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-05-09 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2023-03-06 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2023-01-24 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2022-08-11 | main | B. Riley Securities | — → Buy | $44 |
- $SAVA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 19
- Justice Dept closes Cassava research misconduct inquiry, ending federal probes - Stock Titan hu, 19 Feb 2026 13
- Cassava Sciences (SAVA) Price Target Increased by 150.00% to 5.10 - Nasdaq Wed, 29 Oct 2025 07
- Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Fri, 19 Dec 2025 08
- Cassava Sciences (SAVA): Evaluating Valuation After CEO’s Major Share Purchase and Alzheimer’s Program Withdrawal - Yahoo Finance Sat, 27 Sep 2025 07
- Cassava Sciences: Fundamentals Update After Big Move On Insider Purchases (NASDAQ:SAVA) - Seeking Alpha hu, 25 Sep 2025 07
- Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Stocktwits Fri, 19 Dec 2025 17
- Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased - TipRanks hu, 19 Feb 2026 14
- Biotech Cassava will pay $31.25M to end investor lawsuit from 2021 - Stock Titan ue, 23 Dec 2025 08
- $SAVA stock is down 23% today. Here's what we see in our data. - Quiver Quantitative Fri, 19 Dec 2025 08
- Cassava Boss Buys Big As Stock Collapses - Yahoo Finance ue, 23 Sep 2025 07
- Biggest stock movers Tuesday: SAVA, CLSK, PLUG, and more - Seeking Alpha ue, 23 Sep 2025 07
- LUCID CAPITAL MARKETS Initiates Coverage of Cassava Sciences (SAVA) with Buy Recommendation - Nasdaq Mon, 06 Oct 2025 07
- Cassava (NASDAQ: SAVA) appoints Dawn C. Bir to board; simufilam TSC study in 2026 - Stock Titan Wed, 22 Oct 2025 07
- Cassava Pops After CEO Buys 150,000 Shares - Yahoo Finance ue, 25 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8600 | 24940 | — | Purchase at price 2.90 per share. | ANDERSON ROBERT EUGENE JR | Director | — | 2025-11-24 00:00:00 | D |
| 1 | 150000 | 414000 | — | Purchase at price 2.76 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-11-20 00:00:00 | I |
| 2 | 73385 | 201809 | — | Purchase at price 2.75 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-11-19 00:00:00 | I |
| 3 | 13725 | 39940 | — | Purchase at price 2.91 per share. | COOK ROBERT CHRISTOPHER | Chief Operating Officer | — | 2025-09-30 00:00:00 | D |
| 4 | 7172 | 16352 | — | Purchase at price 2.28 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-09-22 00:00:00 | I |
| 5 | 237941 | 534743 | — | Purchase at price 2.13 - 2.29 per share. | BARRY RICHARD J | Chief Executive Officer | — | 2025-09-19 00:00:00 | I |
| 6 | 61800 | 238468 | — | Sale at price 3.82 - 3.86 per share. | SCHOEN ERIC J. | Chief Financial Officer | — | 2024-11-29 00:00:00 | D/I |
| 7 | 50000 | 59000 | — | Conversion of Exercise of derivative security at price 1.18 per share. | SCHOEN ERIC J. | Chief Financial Officer | — | 2024-11-29 00:00:00 | D |
| 8 | 4000 | 15480 | — | Sale at price 3.87 per share. | KUPIEC JAMES WILLIAM | Officer | — | 2024-11-29 00:00:00 | D |
| 9 | 5000 | — | — | Stock Gift at price 0.00 per share. | ROBERTSON SANFORD R | Director | — | 2024-05-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -249.33M | -105.80M | -80.18M | -32.33M |
| TotalUnusualItems | 108.18M | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 108.18M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.34M | -97.22M | -76.25M | -32.38M |
| ReconciledDepreciation | 1.13M | 1.53M | 1.30M | 534.00K |
| EBITDA | -141.15M | -105.80M | -80.18M | -32.33M |
| EBIT | -142.28M | -107.33M | -81.48M | -32.87M |
| NetInterestIncome | 8.51M | 7.83M | 2.78M | 49.00K |
| InterestIncome | 8.51M | 7.83M | 2.78M | 49.00K |
| NormalizedIncome | -132.53M | -97.22M | -76.25M | -32.38M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.34M | -97.22M | -76.25M | -32.38M |
| TotalExpenses | 142.28M | 107.33M | 81.48M | 32.87M |
| TotalOperatingIncomeAsReported | -141.45M | -105.96M | -80.02M | -32.87M |
| DilutedAverageShares | 4.66B | 41.93M | 40.20M | 39.41M |
| BasicAverageShares | 46.33M | 41.93M | 40.20M | 39.41M |
| DilutedEPS | -1.46 | -2.32 | -1.90 | -0.82 |
| BasicEPS | -0.53 | -2.32 | -1.90 | -0.82 |
| DilutedNIAvailtoComStockholders | -68.14M | -97.22M | -76.25M | -32.38M |
| AverageDilutionEarnings | -43.79M | 0.00 | 0.00 | |
| NetIncomeCommonStockholders | -24.34M | -97.22M | -76.25M | -32.38M |
| NetIncome | -24.34M | -97.22M | -76.25M | -32.38M |
| NetIncomeIncludingNoncontrollingInterests | -24.34M | -97.22M | -76.25M | -32.38M |
| NetIncomeContinuousOperations | -24.34M | -97.22M | -76.25M | -32.38M |
| PretaxIncome | -24.34M | -97.22M | -76.25M | -32.38M |
| OtherIncomeExpense | 109.43M | 2.28M | 2.46M | 434.00K |
| OtherNonOperatingIncomeExpenses | 1.24M | 2.28M | 2.46M | 434.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfPPE | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | 108.18M | |||
| NetNonOperatingInterestIncomeExpense | 8.51M | 7.83M | 2.78M | 49.00K |
| InterestIncomeNonOperating | 8.51M | 7.83M | 2.78M | 49.00K |
| OperatingIncome | -142.28M | -107.33M | -81.48M | -32.87M |
| OperatingExpense | 142.28M | 107.33M | 81.48M | 32.87M |
| OtherOperatingExpenses | 832.00K | 1.38M | 1.46M | |
| ResearchAndDevelopment | 69.64M | 89.42M | 68.03M | 24.81M |
| SellingGeneralAndAdministration | 71.81M | 16.53M | 11.99M | 8.05M |
| GeneralAndAdministrativeExpense | 71.81M | 16.53M | 11.99M | 8.05M |
| OtherGandA | 71.81M | 16.53M | 11.99M | 8.05M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 48.20M | 42.24M | 41.74M | 40.02M |
| ShareIssued | 48.20M | 42.24M | 41.74M | 40.02M |
| TotalDebt | 0.00 | 139.00K | 236.00K | |
| TangibleBookValue | 145.67M | 137.29M | 226.92M | 252.84M |
| InvestedCapital | 145.70M | 137.47M | 227.54M | 253.91M |
| WorkingCapital | 124.78M | 115.44M | 204.16M | 231.95M |
| NetTangibleAssets | 145.67M | 137.29M | 226.92M | 252.84M |
| CapitalLeaseObligations | 0.00 | 139.00K | 236.00K | |
| CommonStockEquity | 145.70M | 137.47M | 227.54M | 253.91M |
| TotalCapitalization | 145.70M | 137.47M | 227.54M | 253.91M |
| TotalEquityGrossMinorityInterest | 145.70M | 137.47M | 227.54M | 253.91M |
| StockholdersEquity | 145.70M | 137.47M | 227.54M | 253.91M |
| RetainedEarnings | -405.11M | -380.77M | -283.55M | -207.31M |
| AdditionalPaidInCapital | 550.77M | 518.20M | 511.05M | 461.18M |
| CapitalStock | 48.00K | 42.00K | 42.00K | 40.00K |
| CommonStock | 48.00K | 42.00K | 42.00K | 40.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 11.83M | 14.20M | 7.29M | 12.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 79.00K | 0.00 | 232.00K | 333.00K |
| OtherNonCurrentLiabilities | 79.00K | 197.00K | 194.00K | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 35.00K | 139.00K | |
| LongTermCapitalLeaseObligation | 0.00 | 35.00K | 139.00K | |
| CurrentLiabilities | 11.75M | 14.20M | 7.06M | 12.53M |
| OtherCurrentLiabilities | 299.00K | 385.00K | 492.00K | 631.00K |
| CurrentDebtAndCapitalLeaseObligation | 104.00K | 97.00K | ||
| CurrentCapitalLeaseObligation | 0.00 | 104.00K | 97.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.36M | 200.00K | 170.00K | 1.88M |
| PayablesAndAccruedExpenses | 10.09M | 13.61M | 6.30M | 9.93M |
| CurrentAccruedExpenses | 2.44M | 3.04M | 2.28M | 2.80M |
| Payables | 7.65M | 10.57M | 4.02M | 7.13M |
| AccountsPayable | 7.65M | 10.57M | 4.02M | 7.13M |
| TotalAssets | 157.53M | 151.66M | 234.83M | 266.78M |
| TotalNonCurrentAssets | 21.00M | 22.03M | 23.61M | 22.30M |
| OtherNonCurrentAssets | 399.00K | |||
| GoodwillAndOtherIntangibleAssets | 37.00K | 176.00K | 622.00K | 1.07M |
| OtherIntangibleAssets | 37.00K | 176.00K | 622.00K | 1.07M |
| NetPPE | 20.96M | 21.85M | 22.99M | 20.83M |
| AccumulatedDepreciation | -3.24M | -2.28M | -1.20M | -396.00K |
| GrossPPE | 24.20M | 24.14M | 24.19M | 21.22M |
| Leases | 3.06M | 3.06M | 3.02M | 567.00K |
| ConstructionInProgress | 55.00K | 0.00 | 13.00K | 83.00K |
| OtherProperties | 494.00K | 494.00K | 470.00K | 470.00K |
| MachineryFurnitureEquipment | 875.00K | 868.00K | 851.00K | 178.00K |
| BuildingsAndImprovements | 15.98M | 15.98M | 16.10M | 16.19M |
| LandAndImprovements | 3.73M | 3.73M | 3.73M | 3.73M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 136.53M | 129.63M | 211.23M | 244.48M |
| OtherCurrentAssets | 38.00K | 287.00K | 160.00K | 53.00K |
| PrepaidAssets | 6.97M | 7.25M | 10.05M | 10.99M |
| Receivables | 947.00K | 962.00K | 0.00 | |
| AccruedInterestReceivable | 947.00K | 962.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 128.57M | 121.14M | 201.01M | 233.44M |
| CashAndCashEquivalents | 128.57M | 121.14M | 201.01M | 233.44M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -117.03M | -82.44M | -80.23M | -52.41M |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 47.33M | 189.82M |
| CapitalExpenditure | -103.00K | -414.00K | -2.71M | -22.21M |
| EndCashPosition | 128.57M | 121.14M | 201.01M | 233.44M |
| BeginningCashPosition | 121.14M | 201.01M | 233.44M | 93.51M |
| ChangesInCash | 7.44M | -79.88M | -32.42M | 139.93M |
| FinancingCashFlow | 124.47M | 2.56M | 47.80M | 192.34M |
| CashFlowFromContinuingFinancingActivities | 124.47M | 2.56M | 47.80M | 192.34M |
| ProceedsFromStockOptionExercised | 124.47M | 2.56M | 475.00K | 2.52M |
| NetCommonStockIssuance | 0.00 | 0.00 | 47.33M | 189.82M |
| CommonStockIssuance | 0.00 | 0.00 | 47.33M | 189.82M |
| InvestingCashFlow | -103.00K | -414.00K | -2.71M | -22.21M |
| CashFlowFromContinuingInvestingActivities | -103.00K | -414.00K | -2.71M | -22.21M |
| NetPPEPurchaseAndSale | -103.00K | -414.00K | -2.71M | -22.21M |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -103.00K | -414.00K | -2.71M | -22.21M |
| OperatingCashFlow | -116.93M | -82.03M | -77.51M | -30.20M |
| CashFlowFromContinuingOperatingActivities | -116.93M | -82.03M | -77.51M | -30.20M |
| ChangeInWorkingCapital | -1.83M | 9.08M | -4.63M | -104.00K |
| ChangeInOtherWorkingCapital | 1.16M | 13.00K | -1.72M | 28.00K |
| ChangeInOtherCurrentLiabilities | -7.00K | -304.00K | -136.00K | 731.00K |
| ChangeInPayablesAndAccruedExpense | -3.52M | 7.65M | -3.97M | 10.09M |
| ChangeInAccruedExpense | -597.00K | 757.00K | -523.00K | 3.88M |
| ChangeInPayable | -2.92M | 6.90M | -3.45M | 6.21M |
| ChangeInAccountPayable | -2.92M | 6.90M | -3.45M | 6.21M |
| ChangeInPrepaidAssets | 539.00K | 1.71M | 1.19M | -10.96M |
| StockBasedCompensation | 16.29M | 4.59M | 2.07M | 1.76M |
| DepreciationAmortizationDepletion | 1.13M | 1.53M | 1.30M | 534.00K |
| DepreciationAndAmortization | 1.13M | 1.53M | 1.30M | 534.00K |
| AmortizationCashFlow | 180.00K | 446.00K | 497.00K | 224.00K |
| AmortizationOfIntangibles | 180.00K | 446.00K | 497.00K | 224.00K |
| Depreciation | 952.00K | 1.08M | 804.00K | 310.00K |
| OperatingGainsLosses | -108.18M | |||
| GainLossOnInvestmentSecurities | -108.18M | |||
| GainLossOnSaleOfPPE | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -24.34M | -97.22M | -76.25M | -32.38M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SAVA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|